|
NI-0401 is a fully human anti-CD3 mAb, which binds and modulates the CD3 epsilon chain expressed on all T cells. This pharmacodynamic effect leads to long term immunomodulation, which is a unique benefit offered by targeting CD3 molecules. NovImmune’s overall program allows for numerous line extensions (Crohn’s disease, type I diabetes [TID], transplantation, multiple sclerosis, atherosclerosis, psoriasis, ulcerative colitis) to create a distinguished franchise around NI-0401 and to potentially offer new effective treatment regimens.
|
| Print |
|
|
|
|
| © NovImmune 2008 |
